Daily Physical Activity and Irisin, Adiponectin, and C-Peptide in Preterm Infants
NCT07924631, Not applicable, Completed, Kayseri City Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Daily Physical Activity and Irisin, Adiponectin, and C-Peptide in Preterm Infants | ClinicalTrials.gov |
| NCT number | NCT07924631 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 54 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Kayseri City Hospital | ClinicalTrials.gov |
| Conditions | Premature, Very Low Birth Weight Infant, Bone Mineralization, Irisin, Adiponectin, C-peptide, Physical Activity | ClinicalTrials.gov |
| Interventions | Range-of-Motion (ROM) Exercise Program, Standard Neonatal Care | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Serum Irisin Concentration | Baseline (Day 0) and post-intervention (Day 30) | Serum irisin levels are quantitatively measured using an enzyme-linked immunosorbent assay (ELISA). The results are expressed in ng/mL. | ClinicalTrials.gov |
| Primary | Change in Serum Adiponectin Concentration | Baseline (Day 0) and post-intervention (Day 30) | Serum adiponectin levels are quantitatively measured using an enzyme-linked immunosorbent assay (ELISA). The results are expressed in ng/mL. | ClinicalTrials.gov |
| Secondary | Change in Serum C-peptide Concentration | Baseline (Day 0) and post-intervention (Day 30) | Serum C-peptide levels are quantitatively measured using an enzyme-linked immunosorbent assay (ELISA). The results are expressed in pg/mL. | ClinicalTrials.gov |
| Secondary | Change in Bone Speed of Sound (SOS) | Baseline (Day 0) and post-intervention (Day 30) | Bone speed of sound (SOS) is assessed as an indicator of bone strength and mineralization using quantitative ultrasound. | ClinicalTrials.gov |
| Secondary | Change in Body Weight | Baseline (Day 0) and post-intervention (Day 30) | Change in body weight measured using a digital scale from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Serum Calcium Concentration | Baseline (Day 0) and post-intervention (Day 30) | Change in serum calcium concentration from baseline to the end of the 30-day intervention period, assessed as a marker of bone metabolism. | ClinicalTrials.gov |
| Secondary | Change in Body Length | Baseline (Day 0) and post-intervention (Day 30) | Change in body length from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Head Circumference | Baseline (Day 0) and post-intervention (Day 30) | Change in head circumference from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Chest Circumference | Baseline (Day 0) and post-intervention (Day 30) | Change in chest circumference from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Abdominal Circumference | Baseline (Day 0) and post-intervention (Day 30) | Change in abdominal circumference from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Tibial Length | Baseline (Day 0) and post-intervention (Day 30) | Change in tibial length from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Mid-Upper Arm Circumference | Baseline (Day 0) and post-intervention (Day 30) | Change in mid-upper arm circumference from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Triceps Skinfold Thickness | Baseline (Day 0) and post-intervention (Day 30) | Change in triceps skinfold thickness measured using a skinfold caliper from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Serum Phosphorus Concentration | Baseline (Day 0) and post-intervention (Day 30) | Change in serum phosphorus concentration from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Serum Magnesium Concentration | Baseline (Day 0) and post-intervention (Day 30) | Change in serum magnesium concentration from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Serum Alkaline Phosphatase (ALP) | Baseline (Day 0) and post-intervention (Day 30) | Change in serum alkaline phosphatase (ALP) from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Serum Parathyroid Hormone (PTH) | Baseline (Day 0) and post-intervention (Day 30) | Change in serum parathyroid hormone (PTH) from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Urinary Calcium Level | Baseline (Day 0) and post-intervention (Day 30) | Change in urinary calcium level from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Urinary Phosphorus Level | Baseline (Day 0) and post-intervention (Day 30) | Change in urinary phosphorus level from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
| Secondary | Change in Urinary Magnesium Level | Baseline (Day 0) and post-intervention (Day 30) | Change in urinary magnesium level from baseline to the end of the 30-day intervention period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)